[{"id":"a9f39237-1737-4421-910a-0e37d38262b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05083754","created_at":"2023-11-27T22:14:37.322Z","updated_at":"2025-02-25T12:28:25.580Z","phase":"Phase 1","brief_title":"Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma","source_id_and_acronym":"NCT05083754","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • MSI • CD8 • PD-1 • CD4 • ICOS","pipe":"","alterations":" ","tags":["PD-L1 • MSI • CD8 • PD-1 • CD4 • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • carmustine • Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-24"},{"id":"71a4afcd-6df8-4c91-9a29-c1843f5eade5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06179160","created_at":"2023-12-21T15:19:06.393Z","updated_at":"2025-02-25T13:50:04.432Z","phase":"Phase 1","brief_title":"A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation","source_id_and_acronym":"NCT06179160","lead_sponsor":"Incyte Corporation","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • irinotecan • Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 466","initiation":"Initiation: 01/04/2024","start_date":" 01/04/2024","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-21"},{"id":"6a10d540-3227-4566-8606-34570d8b161e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04580485","created_at":"2021-02-24T11:03:20.215Z","updated_at":"2025-02-25T14:07:56.143Z","phase":"Phase 1","brief_title":"INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors","source_id_and_acronym":"NCT04580485","lead_sponsor":"Incyte Corporation","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • INCB106385"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 02/03/2021","start_date":" 02/03/2021","primary_txt":" Primary completion: 01/22/2024","primary_completion_date":" 01/22/2024","study_txt":" Completion: 01/22/2024","study_completion_date":" 01/22/2024","last_update_posted":"2025-02-18"},{"id":"22e86fd8-4f8f-4456-992c-88f257edf9a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05345002","created_at":"2022-04-25T21:58:14.873Z","updated_at":"2025-02-25T14:41:19.773Z","phase":"Phase 2","brief_title":"All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma","source_id_and_acronym":"NCT05345002","lead_sponsor":"Stephen Bagley, MD, MSCE","biomarkers":" IDH1 • IDH2 • MGMT","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-14"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"5351b2fd-adc5-41e4-92bd-076122f48c07","acronym":"BRI-ROL-001","url":"https://clinicaltrials.gov/study/NCT03328026","created_at":"2021-01-18T16:26:04.427Z","updated_at":"2025-02-25T16:52:02.280Z","phase":"Phase 1/2","brief_title":"Combination Study of SV-BR-1-GM With Retifanlimab","source_id_and_acronym":"NCT03328026 - BRI-ROL-001","lead_sponsor":"BriaCell Therapeutics Corporation","biomarkers":" ER • PIK3CA • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive","tags":["ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360) • Bria-IMT (SV-BR-1-GM) • Intron A (interferon α-2b) • cyclophosphamide intravenous"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 36","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 11/03/2025","primary_completion_date":" 11/03/2025","study_txt":" Completion: 11/30/2028","study_completion_date":" 11/30/2028","last_update_posted":"2025-02-04"},{"id":"9455efaa-e977-4616-8644-72913019ad15","acronym":"","url":"https://clinicaltrials.gov/study/NCT04989387","created_at":"2021-08-04T13:52:52.724Z","updated_at":"2025-02-25T16:16:34.090Z","phase":"Phase 1","brief_title":"Study of INCA 0186 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT04989387","lead_sponsor":"Incyte Corporation","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • INCB106385 • uprevstobart (INCA00186)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 10/04/2021","start_date":" 10/04/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-11-06"},{"id":"96e420b5-20d6-444c-80a7-976e582c147d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05440942","created_at":"2022-07-01T21:55:26.997Z","updated_at":"2025-02-25T15:54:31.335Z","phase":"Phase 1","brief_title":"Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT05440942","lead_sponsor":"Peter Hosein, MD","biomarkers":" TMB • BRCA1 • BRCA2 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["TMB • BRCA1 • BRCA2 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Jakafi (ruxolitinib) • Zynyz (retifanlimab-dlwr)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 01/19/2023","start_date":" 01/19/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-09-11"},{"id":"ae811060-6784-4e84-9e0a-a82e8350a70e","acronym":"POD1UM-101","url":"https://clinicaltrials.gov/study/NCT03059823","created_at":"2021-01-17T17:36:14.840Z","updated_at":"2024-07-02T16:34:26.332Z","phase":"Phase 1","brief_title":"A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03059823 - POD1UM-101","lead_sponsor":"Incyte Corporation","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr)"],"overall_status":"Completed","enrollment":" Enrollment 325","initiation":"Initiation: 11/15/2016","start_date":" 11/15/2016","primary_txt":" Primary completion: 05/22/2024","primary_completion_date":" 05/22/2024","study_txt":" Completion: 05/22/2024","study_completion_date":" 05/22/2024","last_update_posted":"2024-06-13"},{"id":"bd75f6cb-9c61-46b7-9c32-2458d8550dad","acronym":"BRIA-ABC","url":"https://clinicaltrials.gov/study/NCT06072612","created_at":"2023-10-10T15:12:12.246Z","updated_at":"2024-07-02T16:34:26.318Z","phase":"Phase 3","brief_title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","source_id_and_acronym":"NCT06072612 - BRIA-ABC","lead_sponsor":"BriaCell Therapeutics Corporation","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • capecitabine • cyclophosphamide • Halaven (eribulin mesylate) • Zynyz (retifanlimab-dlwr) • Bria-IMT (SV-BR-1-GM)"],"overall_status":"Recruiting","enrollment":" Enrollment 404","initiation":"Initiation: 12/05/2023","start_date":" 12/05/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-13"},{"id":"43f66187-5b30-4357-8f5c-84f785cedc80","acronym":"POD1UM-204","url":"https://clinicaltrials.gov/study/NCT04463771","created_at":"2021-01-18T21:27:26.857Z","updated_at":"2024-07-02T16:34:37.736Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.","source_id_and_acronym":"NCT04463771 - POD1UM-204","lead_sponsor":"Incyte Corporation","biomarkers":" PD-L1 • MSI • POLE","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • FGFR mutation • FGFR1 mutation","tags":["PD-L1 • MSI • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • FGFR mutation • FGFR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib) • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360) • tuparstobart (INCAGN2385) • verzistobart (INCAGN2390)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-06-06"},{"id":"8ca01846-5fd8-4a2a-a6c9-f8da5e055a47","acronym":"POD1UM-303","url":"https://clinicaltrials.gov/study/NCT04472429","created_at":"2021-01-29T07:20:57.236Z","updated_at":"2024-07-02T16:34:37.843Z","phase":"Phase 3","brief_title":"Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).","source_id_and_acronym":"NCT04472429 - POD1UM-303","lead_sponsor":"Incyte Corporation","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Zynyz (retifanlimab-dlwr)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 308","initiation":"Initiation: 01/12/2021","start_date":" 01/12/2021","primary_txt":" Primary completion: 10/24/2024","primary_completion_date":" 10/24/2024","study_txt":" Completion: 10/27/2024","study_completion_date":" 10/27/2024","last_update_posted":"2024-06-06"},{"id":"e726abe0-9a61-4e1d-8970-9b7613e8839f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03522142","created_at":"2021-01-18T17:20:30.581Z","updated_at":"2024-07-02T16:34:37.560Z","phase":"Phase 1","brief_title":"A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies","source_id_and_acronym":"NCT03522142","lead_sponsor":"Incyte Corporation","biomarkers":" FLT3 • MSI • IDH1 • IDH2","pipe":" | ","alterations":" MSI-H/dMMR • FLT3-ITD mutation • FLT3 wild-type • IDH wild-type","tags":["FLT3 • MSI • IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • FLT3-ITD mutation • FLT3 wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • INCB81776"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 08/27/2018","start_date":" 08/27/2018","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-06"},{"id":"3fa8b4e4-5808-4ba8-b524-7db4cfb6614d","acronym":"MAHOGANY","url":"https://clinicaltrials.gov/study/NCT04082364","created_at":"2021-01-17T17:54:33.576Z","updated_at":"2024-07-02T16:35:03.564Z","phase":"Phase 2/3","brief_title":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","source_id_and_acronym":"NCT04082364 - MAHOGANY","lead_sponsor":"MacroGenics","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • 5-fluorouracil • capecitabine • oxaliplatin • Margenza (margetuximab-cmkb) • Zynyz (retifanlimab-dlwr) • tebotelimab (MGD013)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 09/30/2019","start_date":" 09/30/2019","primary_txt":" Primary completion: 01/15/2024","primary_completion_date":" 01/15/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-05-15"},{"id":"29a2a8bd-7f56-4d48-a7d1-590b9ec36938","acronym":"","url":"https://clinicaltrials.gov/study/NCT04370704","created_at":"2021-01-18T21:07:06.059Z","updated_at":"2024-07-02T16:35:07.530Z","phase":"Phase 1/2","brief_title":"Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies","source_id_and_acronym":"NCT04370704","lead_sponsor":"Incyte Corporation","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • tuparstobart (INCAGN2385) • verzistobart (INCAGN2390)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 07/27/2020","start_date":" 07/27/2020","primary_txt":" Primary completion: 08/04/2025","primary_completion_date":" 08/04/2025","study_txt":" Completion: 08/04/2025","study_completion_date":" 08/04/2025","last_update_posted":"2024-04-25"},{"id":"ac98ef23-c100-4250-a77b-e2d769f12f8d","acronym":"NCI-2020-02940","url":"https://clinicaltrials.gov/study/NCT04445844","created_at":"2021-01-18T21:23:42.652Z","updated_at":"2024-07-02T16:35:11.834Z","phase":"Phase 2","brief_title":"INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study","source_id_and_acronym":"NCT04445844 - NCI-2020-02940","lead_sponsor":"Mridula George, MD","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression • ER expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression • ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • Zynyz (retifanlimab-dlwr) • Reolysin (pelareorep)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-04-02"},{"id":"8fd31dd0-c717-4033-9f44-afbf209f365e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04225039","created_at":"2021-03-09T19:53:36.498Z","updated_at":"2024-07-02T16:35:12.728Z","phase":"Phase 2","brief_title":"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma","source_id_and_acronym":"NCT04225039","lead_sponsor":"University of Pennsylvania","biomarkers":" MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • ragifilimab (INCAGN1876)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 06/23/2020","start_date":" 06/23/2020","primary_txt":" Primary completion: 09/08/2022","primary_completion_date":" 09/08/2022","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-26"},{"id":"24b439dc-7d7b-496b-a965-b7e47c369dd2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05743595","created_at":"2023-02-24T16:01:26.750Z","updated_at":"2024-07-02T16:35:16.529Z","phase":"Phase 1","brief_title":"Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma","source_id_and_acronym":"NCT05743595","lead_sponsor":"Washington University School of Medicine","biomarkers":" IDH1 • IDH2 • MGMT","pipe":" | ","alterations":" IDH2 mutation • MGMT promoter methylation • IDH wild-type","tags":["IDH1 • IDH2 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • MGMT promoter methylation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • neoantigen DNA vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/27/2023","start_date":" 10/27/2023","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2024-03-04"},{"id":"dccf2f76-76e4-4c57-9da3-30316fd549b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05287113","created_at":"2022-03-18T11:54:30.411Z","updated_at":"2024-07-02T16:35:17.799Z","phase":"Phase 2","brief_title":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","source_id_and_acronym":"NCT05287113","lead_sponsor":"Incyte Biosciences International Sàrl","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • tuparstobart (INCAGN2385) • verzistobart (INCAGN2390)"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 05/21/2024","primary_completion_date":" 05/21/2024","study_txt":" Completion: 09/15/2024","study_completion_date":" 09/15/2024","last_update_posted":"2024-02-23"},{"id":"099c10c0-ef78-481a-99a8-5823e77b325c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04470024","created_at":"2021-01-29T07:20:56.485Z","updated_at":"2024-07-02T16:35:41.337Z","phase":"Phase 1","brief_title":"Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC","source_id_and_acronym":"NCT04470024","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • DPV-001 • ragifilimab (INCAGN1876)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 08/05/2021","start_date":" 08/05/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2023-08-01"},{"id":"9890b512-7ca3-4d21-83a6-d06d0be49182","acronym":"POD1UM-203","url":"https://clinicaltrials.gov/study/NCT03679767","created_at":"2021-01-18T18:02:39.202Z","updated_at":"2024-07-02T16:35:42.372Z","phase":"Phase 2","brief_title":"A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)","source_id_and_acronym":"NCT03679767 - POD1UM-203","lead_sponsor":"Incyte Corporation","biomarkers":" PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr)"],"overall_status":"Completed","enrollment":" Enrollment 121","initiation":"Initiation: 01/09/2019","start_date":" 01/09/2019","primary_txt":" Primary completion: 04/15/2021","primary_completion_date":" 04/15/2021","study_txt":" Completion: 06/28/2022","study_completion_date":" 06/28/2022","last_update_posted":"2023-07-21"},{"id":"219083fe-8a44-4c6b-b797-7dc19744614b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03597295","created_at":"2021-01-29T07:17:39.609Z","updated_at":"2024-07-02T16:36:00.206Z","phase":"Phase 2","brief_title":"A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)","source_id_and_acronym":"NCT03597295","lead_sponsor":"Incyte Corporation","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr)"],"overall_status":"Completed","enrollment":" Enrollment 94","initiation":"Initiation: 10/08/2018","start_date":" 10/08/2018","primary_txt":" Primary completion: 06/08/2020","primary_completion_date":" 06/08/2020","study_txt":" Completion: 11/10/2021","study_completion_date":" 11/10/2021","last_update_posted":"2022-11-17"},{"id":"c59140a0-25cc-462a-8fa0-14d8fcd877e6","acronym":"AuspiCiOus","url":"https://clinicaltrials.gov/study/NCT05177133","created_at":"2022-01-04T13:53:42.957Z","updated_at":"2024-07-02T16:36:03.789Z","phase":"Phase 2","brief_title":"Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)","source_id_and_acronym":"NCT05177133 - AuspiCiOus","lead_sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","biomarkers":" HER-2 • IFNG • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" HER-2 positive • MSI-H/dMMR • HER-2 negative • IFNG expression","tags":["HER-2 • IFNG • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MSI-H/dMMR • HER-2 negative • IFNG expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/05/2021","start_date":" 11/05/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/04/2029","study_completion_date":" 11/04/2029","last_update_posted":"2022-09-16"},{"id":"c56c0875-2077-4738-8cc2-b258916ee607","acronym":"","url":"https://clinicaltrials.gov/study/NCT03406949","created_at":"2021-01-18T16:48:34.491Z","updated_at":"2024-07-02T16:36:10.175Z","phase":"Phase 1","brief_title":"MGD009/MGA012 Combination in Relapsed/Refractory Cancer","source_id_and_acronym":"NCT03406949","lead_sponsor":"MacroGenics","biomarkers":" CD276","pipe":" | ","alterations":" PD-L1 expression • CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • obrindatamab (MGD009)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 02/27/2018","start_date":" 02/27/2018","primary_txt":" Primary completion: 04/27/2022","primary_completion_date":" 04/27/2022","study_txt":" Completion: 04/27/2022","study_completion_date":" 04/27/2022","last_update_posted":"2022-05-19"}]